Great Point Partners LLC
Great Point Partners LLC reported 45 holdings worth US$418M as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
Great Point Partners LLC reported 45 holdings worth US$418M as of Sep 30, 2026. Largest: Vera Therapeutics, Inc., Vor Biopharma Inc. and Amylyx Pharmaceuticals, Inc. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 45
- Value as reported
- US$418M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Vera Therapeutics, Inc. | 809K | US$26.1M | 6.2% |
| Vor Biopharma Inc. | 1.13M | US$21.5M | 5.1% |
| Amylyx Pharmaceuticals, Inc. | 700K | US$20.4M | 4.9% |
| Sagimet Biosciences Inc. - Series A | 1.96M | US$19.4M | 4.6% |
| Definium Therapeutics, Inc. | 509K | US$19.4M | 4.6% |
| Ionis Pharmaceuticals, Inc. | 420K | US$18.8M | 4.5% |
| Genmab A/S | 525K | US$18.7M | 4.5% |
| Zura Bio Limited | 4.08M | US$17M | 4.1% |
| LB Pharmaceuticals Inc | 410K | US$15.8M | 3.8% |
| Abivax SA | 155K | US$15.3M | 3.7% |
| Annexon, Inc. | 3.5M | US$14.8M | 3.5% |
| Belite Bio, Inc. | 75,000 | US$12.7M | 3.0% |
| Eupraxia Pharmaceuticals, Inc. | 1.2M | US$10.9M | 2.6% |
| Nektar Therapeutics | 175K | US$10.6M | 2.5% |
| Climb Bio, Inc. | 800K | US$9.18M | 2.2% |
| AbCellera Biologics Inc. | 600K | US$8.75M | 2.1% |
| Neurogene Inc. | 300K | US$8.35M | 2.0% |
| COMPASS Pathways Plc | 500K | US$6.22M | 1.5% |
| JATT II Acquisition Corp | 500K | US$5.62M | 1.3% |
| Research Alliance Corporation III | 505K | US$5.47M | 1.3% |
| Bright Minds Biosciences Inc. | 110K | US$5.46M | 1.3% |
| Amanat Acquisition Corp | 500K | US$5.34M | 1.3% |
| Altimmune, Inc. | 1.74M | US$4.98M | 1.2% |
| JATT III Acquisition Corp | 450K | US$4.96M | 1.2% |
| Cullinan Therapeutics, Inc. | 300K | US$4.61M | 1.1% |
| Cybin, Inc. | 321K | US$3.94M | 0.94% |
| Rezolute, Inc. | 952K | US$3.94M | 0.94% |
| Opus Genetics, Inc. | 777K | US$3.76M | 0.90% |
| Enliven Therapeutics, Inc. | 70,000 | US$3.21M | 0.77% |
| Relmada Therapeutics, Inc. | 842K | US$3.17M | 0.76% |
| DBV Technologies SA | 250K | US$2.94M | 0.70% |
| Evommune, Inc. | 325K | US$2.68M | 0.64% |
| Contineum Therapeutics, Inc. | 186K | US$2.5M | 0.60% |
| Oruka Therapeutics, Inc. | 24,649 | US$2.05M | 0.49% |
| Humacyte, Inc. | 3.75M | US$1.94M | 0.46% |
| Rein Therapeutics, Inc. | 1.66M | US$1.34M | 0.32% |
| Research Alliance Corporation IV | 106K | US$1.28M | 0.31% |
| Alumis Inc. | 0 | US$0 | 0.00% |
| Immix Biopharma, Inc. | 0 | US$0 | 0.00% |
| Palisade Bio, Inc. | 0 | US$0 | 0.00% |
| ProMIS Neurosciences Inc. | 0 | US$0 | 0.00% |
Source
Download original · View original at SEC
Related